自拍无码精品一区二区|亚洲А∨天堂久久精品|国产日韩欧美一区二区视|亚洲av高清dvd丝袜|中文一级无码黄片精品视频|亚洲无码网站在线免费观看|免费无码又爽又刺激又污又黄|成人免费无码婬片在线观看免费

  • <tfoot id="icskm"></tfoot>
  • <code id="icskm"><xmp id="icskm"></xmp></code>
  • <li id="icskm"><input id="icskm"></input></li>
    <code id="icskm"></code>
  • <cite id="icskm"><center id="icskm"></center></cite><button id="icskm"><bdo id="icskm"></bdo></button><code id="icskm"></code>
  • <cite id="icskm"><pre id="icskm"></pre></cite>
    <button id="icskm"></button>
  • <rt id="icskm"><pre id="icskm"></pre></rt>
    <cite id="icskm"></cite>
    <li id="icskm"></li>
    <button id="icskm"><input id="icskm"></input></button>
  • 159-2642-3062 027-65317797
    服務熱線(工作日:9:00-17:30)

    瀏覽量: 192

    • 產品名稱: Research Grade Ravulizumab ( 雷夫利珠單抗 )
    • 產品貨號: CSD00472
    • 貨期: 現(xiàn)貨
    • 價格與訂購: 2480
    • 數量:
      庫存: 100
    • 規(guī)格: 100μg
    • 產品信息
    • 如何訂購
      貨號(Catalog No.)
      CSD00472
      通用名INN
      Ravulizumab
      純度(Purity)
      >95%
      濃度( Concentration)
      1mg/ml
      Formulation
      PBS buffer PH7.5
      Source
      CHO cells
      內毒素(Endotoxin level)
      Please contact with the lab for this information.
      產品描述(Description)
      Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris?. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a "next-generation" eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label.
      別名(Alternative names)
      ALXN-1210,ravulizumab-cwvz
      靶點;物種(Specificity target name;species)
      C5[Homo sapiens]
      種類(Species)
      Humanized
      受體鑒定(Receptor identification)
      IgG2-G4-kappa
      CAS
      1803171-55-2
      存儲條件(Storage)
      Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
      Store at +4°C short term (1-2 weeks).
      Store at -20 °C 12 months.
      Store at -80°C long term.
      Note
      For research use only .
    玛纳斯县| 苏尼特右旗| 阿尔山市| 阳山县| 托克托县| 丽水市| 长子县| 彩票| 庐江县| 天峻县| 丹阳市| 福鼎市| 澳门| 勐海县| 巴楚县| 乐亭县| 宜宾市| 建德市| 渑池县| 民权县| 平邑县| 资兴市| 鲁山县| 武穴市| 崇义县| 布尔津县| 佛冈县| 商南县| 夹江县| 四平市| 扬州市| 延边| 东城区| 滦平县| 郸城县| 阿图什市| 噶尔县| 收藏| 东乌| 比如县| 遂溪县|